Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Methods/line 113-124/ paragraph3, line 128-141/ paragraph4, line 145-156/ paragraph5-6, line160-166 / paragraph7	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Methods/line 94-98/ paragraph1	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Methods/line 94-98/ paragraph1	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		n/a Not applicable
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a Not applicable
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		n/a Not applicable

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a Not applicable
Microbes: provide species and strain, unique accession number if available, and source		n/a Not applicable

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a Not applicable
Provide statement confirming informed consent obtained from study participants.		n/a Not applicable
Report on age and sex for all study participants.		n/a Not applicable

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		n/a Not applicable

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		n/a Not applicable

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		n/a Not applicable
Randomisation		n/a Not applicable
Blinding		n/a Not applicable
Inclusion/exclusion criteria		n/a Not applicable

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Methods/line 140-141/ paragraph4, line 165-166/ paragraph7	
Define whether data describe technical or biological replicates	Methods/line 140-141/ paragraph4, line 165-166/ paragraph7	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a Not applicable
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a Not applicable
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Footnote/line 392-395/ paragraph4	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a Not applicable

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		n/a Not applicable

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Methods/line 199-211/ paragraph12	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Footnote/line 384-385/ paragraph2	
If data are publicly available, provide accession number in repository or DOI or URL.		n/a Not applicable
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a Not applicable

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		n/a Not applicable
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a Not applicable

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed as the journal follows ICMJE guidelines for publication.	

Article information: https://dx.doi.org/10.21037/tcr-22-2276